Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-02-13 00:00:00 ET · period of report 2024-02-09 · accession 0001968202-24-000064 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-13 | 2024-02-09 | REGN | Van Plew Daniel P | EVP, General Mgr, Industrial | M - OptEx | $378.30 | +35.4K | 32.6K | New | +$13.38M |
| DM | 2024-02-13 | 2024-02-09 | REGN | Van Plew Daniel P | EVP, General Mgr, Industrial | F - Tax | $951.68 | -24.9K | 24.0K | -51% | -$23.74M |
| DM | 2024-02-13 | 2024-02-09 | REGN | Van Plew Daniel P | EVP, General Mgr, Industrial | M - OptEx | $0.00 | -35.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-09 | M | A | 23,125 | $381.40 | 47,153 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-09 | F | D | 16,341 | $951.68 | 30,812 | D | — | — | |
| 3 | Common | Common Stock | 2024-02-09 | M | A | 12,250 | $372.46 | 32,628 | D | — | — | |
| 4 | Common | Common Stock | 2024-02-09 | F | D | 8,600 | $951.68 | 24,028 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-02-09 | M | D | 12,250 | $0.00 | 12,250 | D | $372.46 · — to 2029-12-11 | 12,250 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-02-09 | M | D | 23,125 | $0.00 | 0 | D | $381.40 · — to 2028-12-12 | 23,125 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |